

NBS08

Newborn Screening for Hemoglobinopathies

This guideline describes the recommended protocols for detecting hemoglobinopathies and thalassemias by population-based newborn screening using dried blood spot specimens.

Early, presymptomatic detection to identify newborns with abnormal hemoglobins is critical because it improves treatment effectiveness.

.....
A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

Clinical and Laboratory Standards Institute

Setting the standard for quality in medical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI *Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute

575 West Valley Road, Suite 2500

Wayne, PA 19087 USA

T: +1.610.688.0100

F: +1.610.688.0700

www.clsi.org

standard@clsi.org

Newborn Screening for Hemoglobinopathies

Bradford L. Therrell, Jr., MS, PhD
Carolyn Hoppe, MD, MPH
Marie Y. Mann, MD, MPH
Mahin Azimi, MT(ASCP)CLS
Aigars Brants, PhD
Sarah E. Brown, FIBMS, CSci
Linda S. Carter, BS, MT(ASCP)
M. Christine Dorley, MS, MT(ASCP)
James R. Eckman, MD
Marco Flamini, MSc
Raven Hardcastle
Cornelis L. Harteveld, PhD
Christopher A. Haynes, PhD
Patricia M. Scott
Raquel Yahyaoui, MD, PhD

Abstract

Clinical and Laboratory Standards Institute guideline NBS08—*Newborn Screening for Hemoglobinopathies* describes the newborn screening (NBS) processes for testing dried blood spot specimens to detect hemoglobinopathies and thalassemias not usually evident at birth. Hemoglobinopathies and thalassemias are clinically significant congenital red blood cell disorders caused by structural or other hemoglobin abnormalities, resulting in various clinical manifestations. Early detection is critical, because without treatment, these conditions lead to increased morbidity and mortality. This guideline discusses various NBS approaches, including equipment considerations, laboratory screening methodologies, short-term and long-term follow-up processes, and future screening possibilities.

Clinical and Laboratory Standards Institute (CLSI). *Newborn Screening for Hemoglobinopathies*. 1st ed. CLSI guideline NBS08 (ISBN 978-1-68440-059-1 [Print]; ISBN 978-1-68440-060-7 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2019.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If you or your organization is not a member and would like to become one, please request a copy of the catalog, contact us at: Telephone: +1.610.688.0100; Fax: +1.610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org.



CLINICAL AND
LABORATORY
STANDARDS
INSTITUTE®

Copyright ©2019 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, derivative product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

Suggested Citation

CLSI. *Newborn Screening for Hemoglobinopathies*. 1st ed. CLSI guideline NBS08. Wayne, PA: Clinical and Laboratory Standards Institute; 2019.

SBN 978-1-68440-059-1 (Print)
ISBN 978-1-68440-060-7 (Electronic)
ISSN 1558-6502 (Print)
ISSN 2162-2914 (Electronic)

Volume 39, Number 12

Committee Membership

Consensus Council

**Dennis J. Ernst, MT(ASCP),
NCPT(NCCT)
Chairholder
Center for Phlebotomy Education
USA**

**Mary Lou Gantzer, PhD, FACB
Vice-Chairholder
USA**

J. Rex Astles, PhD, FACB, DABCC
Centers for Disease Control and
Prevention
USA

Thomas R. Fritsche, MD, PhD, FCAP,
FIDSA
Marshfield Clinic
USA

Loralie J. Langman, PhD, DABCC,
FACB, F-ABFT
Mayo Clinic
USA

Michelle McLean, MS, MT(ASCP)
Greiner Bio-One, Inc.
USA

Tania Motschman, MS,
MT(ASCP)SBB
Laboratory Corporation of America
USA

James R. Petisce, PhD
BD Diagnostic Systems
USA

Robert Rej, PhD
New York State Department of
Health – Wadsworth Center
USA

Zivana Tezak, PhD
FDA Center for Devices and
Radiological Health
USA

Document Development Committee on Newborn Screening for Hemoglobinopathies

**Bradford L. Therrell, Jr., MS, PhD
Chairholder
University of Texas Health Science
Center at San Antonio
USA**

**Carolyn Hoppe, MD, MPH
Vice-Chairholder
UCSF Benioff Children's Hospital
Oakland
USA**

**Marie Y. Mann, MD, MPH
Committee Secretary
USA**

Aigars Brants, PhD
USA

Sarah E. Brown, FIBMS, CMAA
Epsom and St Helier NHS Trust
United Kingdom

M. Christine Dorley, M.S., MT(ASCP)
Tennessee Department of Health
USA

James R. Eckman, MD
Errol, University School of Medicine
USA

Marco Flamini, MSc
Bio-Rad Laboratories, Inc.
USA

Cornelis L. Hartevelde, PhD
Leiden University Medical Center
the Netherlands

Christopher A. Haynes, PhD
Centers for Disease Control and
Prevention
USA

Staff

Clinical and Laboratory Standards
Institute
USA

Lori T. Moon, MS, MT(ASCP)
Project Manager

Tabitha Keen, MS, MLS(ASCP)^{CM}
Project Manager

Megan L. Tertel, MA, ELS
Editorial Manager

Catherine E.M. Jenkins
Editor

Kristy L. Leirer, MS
Editor

Laura Martin
Editor

NBS08

Acknowledgment for the Expert Panel on Newborn Screening

CLSI, the Consensus Council, and the Document Development Committee on Preterm Newborn Screening gratefully acknowledge the Expert Panel on Newborn Screening for serving as technical advisors and subject matter experts during the development of this guideline.

Expert Panel on Newborn Screening

Ronald J. Whitley, PhD, DABCC, FACB
Chairholder
University of Kentucky Medical Center
 USA

Amy Gaviglio, MS, CGC
Vice-Chairholder
Minnesota Department of Health
 USA

Ralph Fingerhut, PhD, FAMH
 University Children's Hospital Zurich
 Switzerland

Debra Freedenberg, MD, PhD,
 FFACMG
 Texas Department of State Health
 Services
 USA

Uttam Garg, PhD, DABCC
 The Children's Mercy Hospital
 USA

Kellie B. Kelm, PhD
 FDA Center for Devices and
 Radiological Health
 USA

Joanne Mei, PhD
 Centers for Disease Control and
 Prevention
 USA

Vamsee Pamula, PhD
 Baebies, Inc.
 USA

Scott Shone, PhD, HCLD(ABB)
 RTI International
 USA

Bradford L. Therrell, Jr., MS, PhD
 University of Texas Health Science
 Center at San Antonio
 USA

Raquel Yahyaoui, MD, PhD
 Malaga Regional University Hospital
 Spain

Acknowledgment

CLSI, the Consensus Council, and the Document Development Committee on Newborn Screening for Hemoglobinopathies gratefully acknowledge the following volunteers for their important contributions to the development of this guideline:

Mahin Azimi, MT(ASCP)CLS
 UCSF Benioff Children's Hospital
 Oakland
 USA

Raven Hardcastle
 Texas Department of State Health
 Services
 USA

Raquel Yahyaoui, MD, PhD
 Malaga Regional University Hospital
 Spain

Linda S. Carter, BS, MT(ASCP)
 USA

Patricia M. Scott
 Delaware Public Health Laboratory
 USA

Contents

Abstract	i
Committee Membership	iii
Foreword	vii
Chapter 1: Introduction	1
1.1 Scope	1
1.2 Background	2
1.3 Standard Precautions	3
1.4 Terminology	3
Chapter 2: Hemoglobinopathy Nomenclature, Pathophysiology, and Clinical Manifestations	7
2.1 Hemoglobin Expression During Development	7
2.2 Nomenclature	8
2.3 Sickle Cell Disorders	12
2.4 Thalassemias	17
2.5 Other Clinically Significant Hemoglobinopathies	20
Chapter 3: Overview of Newborn Screening Programs for Hemoglobinopathies	21
Chapter 4: Preanalytical Process Considerations for Newborn Screening for Hemoglobinopathies	23
4.1 Specimen Collection	24
4.2 Specimen Transportation	24
4.3 Specimen Receipt and Storage	26
4.4 Specimen Quality and Acceptability	26
Chapter 5: Analytical Activities for Newborn Screening for Hemoglobinopathies	27
5.1 Classical Electrophoresis: Cellulose Acetate and Citrate Agar	27
5.2 Isoelectric Focusing	28
5.3 High-Performance Liquid Chromatography	28
5.4 Capillary Electrophoresis	29
5.5 Tandem Mass Spectrometry	29
5.6 Molecular Laboratory Techniques	31
5.7 Next-Generation Sequencing	32
5.8 Other Laboratory Approaches	33
5.9 Results Review, Interpretation, and Follow-up	33
5.10 Confirmatory Testing	34
Chapter 6: Postanalytical Activities and Considerations for Newborn Screening for Hemoglobinopathies	35
6.1 Reporting Hemoglobinopathy Newborn Screening Test Results	36
6.2 Short-Term Follow-up	39
6.3 Long-Term Follow-up	40
6.4 Education	41
6.5 Research Opportunities	41

Contents (Continued)

Chapter 7: Conclusion.....	42
Chapter 8: Supplemental Information.....	42
References.....	43
Additional Resources.....	51
Appendix A. Classical Electrophoresis: Cellulose Acetate.....	52
Appendix B. Classical Electrophoresis: Citrate Agar.....	59
Appendix C. Isoelectric Focusing.....	66
Appendix D. High-Performance Liquid Chromatography.....	73
Appendix E. Capillary Electrophoresis.....	79
Appendix F. Electrospray Ionization Tandem Mass Spectrometry.....	84
Appendix G. Real-Time Polymerase Chain Reaction.....	88
Appendix H. Polymerase Chain Reaction–Restriction Fragment Length Polymorphism.....	93
Appendix I. Sanger Sequencing.....	99
The Quality Management System Approach.....	106
Related CLSI Reference Materials.....	107

Foreword

Since the implementation of universal newborn dried blood spot (DBS) screening, mortality in children with sickle cell disease (SCD) aged 1 to 4 years has decreased by 50%.¹⁻⁵ This dramatic decline in mortality is believed to result from multiple interventions, including early initiation of penicillin prophylaxis.⁶ Timely interventions are made possible by early diagnosis, which results from newborn DBS screening coupled with comprehensive follow-up diagnostic testing.

Sickling disorders and thalassemias are among the most prevalent monogenetic diseases worldwide. The screening techniques currently used are primarily based on US experiences and have the longest history and most comprehensive use. The significant effects of hemoglobinopathies on US health care over time, particularly sickle cell anemia and other forms of SCD, can be measured by the availability of various SCD-related federal and state public health programs and funding streams.⁷ Partially because of these programs, universal newborn DBS screening for hemoglobinopathies is now required in all 50 states, the District of Columbia, and many US territories. As of 2016, full-population hemoglobinopathy DBS screening also exists in eight Canadian provinces, seven European countries, and three Latin American countries. Additionally, pilot or targeted hemoglobinopathy screening exists in several other European, Latin American, Asian, Middle Eastern, and African countries.⁸ Although newborn DBS screening has primarily focused on sickle hemoglobinopathies, there is increasing interest in newborn DBS screening for thalassemias, particularly in the Middle East and parts of Europe and Asia.

Various approaches to newborn DBS screening for hemoglobinopathies are used internationally. Variability exists not only in newborn screening (NBS) laboratory procedures but also in screening algorithms, results reporting, and patient follow-up. This guideline has been developed recognizing that although hemoglobinopathy NBS is expanding worldwide, no other international, harmonizing resource is currently available. The comprehensive training and methodological guidance originally developed in the 1970s and 1980s are no longer readily available. Additionally, available hemoglobinopathy screening manuals are outdated.⁹⁻¹¹ Although some regulatory and quality improvement assistance is available to laboratories in the United States¹² and Europe,¹³ it was not designed to harmonize the NBS program differences that currently exist. Guidance is needed to provide an accessible reference for basic newborn DBS screening and to assist NBS programs and medical professionals worldwide who may be initiating, expanding, or harmonizing newborn DBS screening for hemoglobinopathies.

NOTE: The content of this guideline is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

Key Words

Hemoglobinopathy, newborn screening, sickle cell anemia, sickle cell disease, thalassemia

Currently in preview, click buy full version

Newborn Screening for Hemoglobinopathies

Chapter 1: Introduction

This chapter includes:

- Guideline’s scope and applicable exclusions
- Background information pertinent to the guideline’s content
- Standard precautions information
- “Note on Terminology” that highlights particular use and/or variation in use of terms and/or definitions
- Terms and definitions used in the guideline
- Abbreviations and acronyms used in the guideline

Hemoglobinopathies are a group of inherited blood disorders characterized by the presence of structural hemoglobin variants or quantitative differences in globin chain production. Results reporting, particularly for carriers, may sometimes be complicated by regulatory and ethical issues. Although many newborn screening (NBS) programs primarily focus on detecting and reporting sickle cell disease (SCD), they may also detect and/or report the presumptive presence of other clinically significant hemoglobin disorders, including both α and β thalassemias, as well as heterozygotes (carriers).

1.1 Scope

This guideline focuses on the NBS laboratory analytical processes for detecting SCD and other clinically significant hemoglobin disorders, including basic information about the biological and clinical features of clinically significant hemoglobinopathies detectable through NBS. It also provides information on preanalytical considerations affecting laboratory detection of hemoglobinopathies in NBS, including dried blood spot (DBS) specimen stability considerations. Various NBS procedures for hemoglobinopathy detection are discussed, with details of the methods included in the appendixes following a general template to allow easier comparisons between the different screening technologies. Terminology and reporting recommendations are included, along with other postanalytical NBS activities, including both short-term follow-up (STFU) activities (tracking and confirmatory testing) and long-term follow-up (LTFU) activities (outcome indicators, registries, care coordination, and access to services).

The guideline’s overall purpose is to provide sufficient information for worldwide quality NBS process implementation, evaluation, and harmonization. This guideline may also inform policymaking for ensuring quality NBS results. Intended users of this guideline include:

- NBS laboratory and associated follow-up personnel
- Hospital personnel managing newborn DBS specimen collection activities, including:
 - Newborn DBS specimen collection supplies management
 - Newborn DBS specimen collection and transmittal process
 - NBS patient follow-up
 - NBS recordkeeping
- Medical personnel advising NBS programs and caring for affected newborns